Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors.

MLA

Falanga, Anna, et al. “Thrombophilic Status May Predict Prognosis in Patients with Metastatic BRAFV600-Mutated Melanoma Who Are Receiving BRAF Inhibitors.” Journal of the American Academy of Dermatology, vol. 74, no. 6, June 2016, p. 1254–1256.e4. EBSCOhost, https://doi.org/10.1016/j.jaad.2015.11.006.

APA

Falanga, A., Marchetti, M., Massi, D., Merelli, B., Verzeroli, C., Russo, L., Rulli, E., Tondini, C., Legramandi, L., Nassini, R., Scatena, C., De Logu, F., Cattaneo, L., & Mandalà, M. (2016). Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors. Journal of the American Academy of Dermatology, 74(6), 1254–1256.e4. https://doi.org/10.1016/j.jaad.2015.11.006

Chicago

Falanga, Anna, Marina Marchetti, Daniela Massi, Barbara Merelli, Cristina Verzeroli, Laura Russo, Eliana Rulli, et al. 2016. “Thrombophilic Status May Predict Prognosis in Patients with Metastatic BRAFV600-Mutated Melanoma Who Are Receiving BRAF Inhibitors.” Journal of the American Academy of Dermatology 74 (6): 1254–1256.e4. doi:10.1016/j.jaad.2015.11.006.